Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression

Gastric Cancer Clinical Trial

Official title:

Prospective, Single Center, Phase II Study of Disitamab Vedotin（RC48) Combined With Sintilimab Plus XELOX for Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06227325
• Other study ID #: RCVDTYPEC067
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: February 1, 2024
• Est. completion date: December 31, 2025

Study information

• Verified date: September 2023
• Source: Henan Cancer Hospital
• Contact: Ying Liu
• Phone: +86-13783604602
• Email: yaya7207[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to observe the efficacy, safety, postoperative pathological response rate and survival benefit of RC48 combined withSintilimab and chemotherapy in perioperative therapy of locally advanced resectable gastric and gastroesophageal junction adenocarcinoma.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 27
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Subjects volunteered to join the study, could complete the signing of the informed consent form, and had good compliance;

2. Aged at least 18-75 years, male or female;

3. Gastric cancer or adenocarcinoma of gastroesophageal junction confirmed by histology and/or cytology is diagnosed as cT3-4aN1-3M0 according to AJCC version 8, and cTNM is diagnosed as cT3-4aN1-3M0 according to endoscopic ultrasonography or enhanced CT/MRI scanning (combined with ultrasonic gastroscopy and diagnostic laparoscopic exploration if necessary), and the researcher evaluates that the lesion is resectable;

4. Have not received systematic treatment for current diseases in the past, including surgical treatment, anti-tumor radiochemotherapy/immunotherapy, etc;

5. Patients who agree to receive radical surgical treatment and have no surgical contraindication as judged by the surgeon.

6. IHC(immuno-histochemistry) results confirmed HER2 expression (defined as IHC 2+and 3+);

7. ECOG (Eastern Cooperative Oncology Group) score 0-1;

8. Expected life = 6 months;

9. The main organs function well and meet the standards:

10. The fertile subjects must use appropriate methods of contraception during the study period and within 120 days after the end of the study. The serum pregnancy test was negative within 7 days before the study was included, and they must be non lactating subjects.

Exclusion Criteria:

1. Malignant diseases other than gastric cancer diagnosed within 5 years prior to initial administration;

2. Known endoscopic signs of active bleeding;

3. The subject is currently participating in an interventional clinical study, or has received other investigational drugs or used investigational devices within 4 weeks prior to initial dosing;

4. Previous treatment with anti-HER2, anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs or drugs targeting another stimulus or synergistic inhibition of T cell receptors;

5. Received systemic systemic treatment with Chinese patent drugs with anti-tumor indications or immunomodulatory drugs (including thymosin, interferon, interleukin, except for local use to control pleural fluid) within 2 weeks before the first administration;

6. An active autoimmune disease requiring systemic treatment (e.g. with disease-modifying drugs, glucocorticoids, or immunosuppressants) has occurred within 2 years prior to first administration. Replacement therapies (such as thyroxine, insulin, or physiologic glucocorticoids for adrenal or pituitary insufficiency) are not considered systemic therapy;

7. Was receiving systemic glucocorticoid therapy (excluding topical glucocorticoids by nasal spray, inhalation, or other route) or any other form of immunosuppressive therapy within 7 days prior to the study's initial administration;

8. Known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation;

9. Known allergy to the drugs used in this study;

10. Has not fully recovered from toxicity and/or complications caused by any intervention before starting treatment (i.e., = grade 1 or baseline, excluding weakness or hair loss);

11. Known history of human immunodeficiency virus (HIV) infection (i.e. HIV 1/2 antibody positive);

12. Untreated active hepatitis B (defined as HBsAg positive and HBV(hepatitis B virus)-DNA copy number detected greater than the upper limit of normal value in the laboratory of the study center);

13. Active HCV-infected subjects (HCV antibody positive and HCV-RNA levels above the lower limit of detection);

14. Received live vaccine within 30 days prior to the first dose (cycle 1, day 1);

15. Pregnant or lactating women;

16. The presence of any serious or uncontrolled systemic disease;

17. Evidence of medical history or disease that might interfere with the test results, prevent participants from fully participating in the study, abnormal treatment or laboratory test values, or other conditions that the investigator considers unsuitable for enrollment The Investigator considers other potential risks unsuitable for participation in the study.

Related Conditions & MeSH terms

• Gastric Cancer
• Stomach Neoplasms

Intervention

Drug:
• RC48 combined with Sintilimab and XELOX
RC48: 2.5 mg/kg, iv, d1, repeat every 2 weeks; Sintilimab: 200mg, iv, d1, repeat every 3 weeks; XELOX: Oxaliplatin 130mg/m2, iv, d1;Capecitabine1000 mg po, bid, d1-14, repeat every 3 weeks

Locations

Country	Name	City	State
China	Henan Cancer Hospital	Zhengzhou	Henan

Sponsors (1)

Lead Sponsor	Collaborator
Henan Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	pathological complete response (pCR) rate	The percentage of patients with no residual cells at the primary cancer site and N(-) per histological evaluation.	Up to approximately 12 weeks
Secondary	R0 resection rate	The percentage of patients who have no residual cancer cells (gross or microscopically) at the resection margins.	Up to approximately 12 weeks
Secondary	Disease free survival (DFS)	DFS is defined as the time from postoperative baseline imaging evaluation to disease recurrence or death in subjects who are disease-free after surgery.	From randomization to the date of recurrence or death (up to approximately 4 years).
Secondary	Major pathological response (MPR) rate		Up to approximately 12 weeks
Secondary	Clinical downgrading rate		Up to approximately 12 weeks
Secondary	Overall survival (OS)	OS is defined as the time from the first dose to all-cause death.	From the randomization to the date of death (up to approximately 4 years).
Secondary	Percentage of Participants who experience one or more adverse events (AEs).	The incidence and grade of adverse events (including SAE) will be determined per NCI-CTCAE 5.0.	Up to approximately 2 years